Literature DB >> 3712391

The relationship between the acetylator and the sparteine hydroxylation polymorphisms.

D Harmer, D A Evans, L C Eze, M Jolly, E J Whibley.   

Abstract

Thirty-eight healthy white British Caucasian subjects were hydroxylator phenotyped with sparteine and acetylator phenotyped with sulphadimidine. The results showed that there was no significant difference in the mean sparteine metabolic ratio between eight rapid acetylator extensive hydroxylators and 27 slow acetylator extensive hydroxylators.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3712391      PMCID： PMC1049571          DOI： 10.1136/jmg.23.2.155

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


  17 in total

1.  Polymorphic acetylation of procaine amide in healthy subjects.

Authors:  E Karlsson; L Molin
Journal:  Acta Med Scand       Date:  1975-04

2.  HUMAN ACETYLATION POLYMORPHISM.

Authors:  D A EVANS; T A WHITE
Journal:  J Lab Clin Med       Date:  1964-03

3.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

4.  The polymorphic acetylation of sulphapyridine in man.

Authors:  H Schröder; D A Evans
Journal:  J Med Genet       Date:  1972-06       Impact factor: 6.318

5.  The use of the autoanalyzer to determine the acetylator phenotype.

Authors:  L C Eze; D A Evans
Journal:  J Med Genet       Date:  1972-03       Impact factor: 6.318

6.  An improved and simplified method of detecting the acetylator phenotype.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1969-12       Impact factor: 6.318

7.  Polymorphic acetylation of nitrazepam.

Authors:  A K Karim; D A Evans
Journal:  J Med Genet       Date:  1976-02       Impact factor: 6.318

8.  Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype.

Authors:  T P Gibson; J Matusik; E Matusik; H A Nelson; J Wilkinson; W A Briggs
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

9.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321
View more
  3 in total

1.  Acetylator polymorphism in Parkinson's disease.

Authors:  J M Ladero; F J Jimenez; J Benitez; M J Fernandez-Gundin; C Martinez; A Llerena; J Cobaleda; J J Muñoz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity.

Authors:  C Adithan; A Subathra
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

3.  Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence.

Authors:  Saif Khan; Raju K Mandal; Abdulbaset Mohamed Elasbali; Sajad A Dar; Arshad Jawed; Mohd Wahid; Harishankar Mahto; Mohtashim Lohani; Bhartendu Nath Mishra; Naseem Akhter; Ali A Rabaan; Shafiul Haque
Journal:  Biosci Rep       Date:  2019-01-15       Impact factor: 3.840
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.